GlassScriptPhysician profile
George A Sanchez
NPI 1053512707
$116,828.56
in general payments reported to CMS, 2019-2025
31 companies · $40K in 2025
The $40K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $4,475 · 2021: $22K · 2022: $10K · 2023: $5,460 · 2024: $7,222 · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $51K · Food and Beverage: $2,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $50,576.67 |
| Food and Beverage | $2,110.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $57,651.94 | 2019-2022 | |
| Capsovision, INC. | $54,576.67 | 2020-2025 | Capsocam Plus, Capsocam Colon |
| Abbvie INC. | $1,470.99 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Pentax of America, INC. | $571.60 | 2019-2022 | |
| Janssen Biotech, INC. | $443.25 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $371.03 | 2019-2023 | Xifaxan |
| Pfizer INC. | $249.41 | 2019-2025 | |
| Celgene Corporation | $201.11 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $150.35 | 2019-2024 | Sucraid |
| Lilly USA, LLC | $140.45 | 2023-2025 | |
| Surmodics, INC. | $137.27 | 2023 | Pounce Thrombectomy, Sublime 014 Rx Pta Balloon Dilatation Catheter, Sublime Radial Access 018 Rx Pta Dilatation Catheter |
| Phathom Pharmaceuticals, INC. | $117.00 | 2024 | Voquezna |
| Ardelyx, INC. | $93.77 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $71.75 | 2021-2025 | Entyvio |
| Redhill Biopharma INC. | $59.51 | 2021-2024 | Talicia, Aemcolo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $59.30 | 2019-2022 | |
| Allergan, INC. | $56.21 | 2019-2020 | |
| Madrigal Pharmaceuticals | $54.79 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $51.34 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $47.35 | 2022-2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $44.14 | 2023-2024 | Dupixent |
| Celltrion USA INC. | $35.01 | 2024 | Vegzelma |
| Merck Sharp & Dohme LLC | $34.75 | 2022-2023 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $34.69 | 2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $18.19 | 2023 | Rebyota |
| Shionogi INC | $16.91 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.33 | 2023 | Linzess |
| Novo Nordisk INC | $14.56 | 2025 | Wegovy |
| Romark Laboratories, Lc | $13.80 | 2019-2020 | |
| Concordia Pharmaceuticals INC. | $13.13 | 2019 | |
| Braintree Laboratories, INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.